Immunovant, Inc. Overview
Pro stress-test →Immunovant is a clinical-stage immunology company that develops monoclonal antibodies for the treatment of autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Despite having no approved products, the company commands a substantial valuation due to its advanced clinical pipeline and strong cash position.
Strategic Profile
Pro stress-test →The company's lead asset, IMVT-1402, is a next-generation neonatal FcRn inhibitor advancing in up to six potentially registrational trials for major autoimmune diseases like Graves' disease and Myasthenia Gravis. The company maintains a war chest of $4.4 billion in cash and cash equivalents as of September 2025, giving it a long runway to execute its development strategy.
Competitive Landscape
Pro stress-test →Immunovant competes within the broader autoimmune therapeutics space against established FcRn inhibitor programs and other monoclonal antibody developers. Key competitors include companies developing alternative mechanisms in autoimmune disease treatment, though Immunovant's multi-indication FcRn platform positions it as a differentiated player if clinical trials succeed.
Industry Context
Immunovant, Inc. operates in Biopharmaceutical - Clinical-Stage Immunology.
Key facts
Founded: 2018 · Headquarters: New York, US · Revenue: $0 · Market cap: $4.26B